Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 369

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 3
Chunk 369
---
 Officer and Director
  
    Freda
    Lewis-Hall
     
    70
     
    Chairperson
    of the Board of Directors
  
    Faith
    L. Charles
     
    63
     
    Director
  
    Chele
    Chiavacci Farley
     
    58
     
    Director
  
    Simon
    Fry
     
    65
     
    Director
  
    Andrew
    Regan
     
    59
     
    Director

Executive
Officers

David
Tapolczay. Dr. Tapolczay has more than 20 years of experience in research and development management. He has served as our Chief
Executive Officer and a member of the board of directors since September 2023. He was a co-founder and served as the Chief Executive
Officer a member of the board of directors of Old Conduit from 2019 until the Business Combination in September 2023. He served as Chief
Executive Officer of St George Street Capital, a United Kingdom-based medical research charity that is a business partner to Conduit,
from July 2018 to September 2023. He also serves as Chief Executive Officer of Medeor Pharma Ltd, a pharmaceutical consultancy company,
a position which he has held since 2006.

From
February 2008 to December 2018, he served as Chief Executive Officer at LifeArc (formerly the Medical Research Counsel Technology Group
(MRCT)), a United-Kingdom based charity advancing lab-based scientific discoveries to a point at which they can be developed into the
next generation of diagnostics, treatments and cures. He previously served as joint worldwide head of chemistry for Zeneca Agrochemicals,
a research and development unit of AstraZeneca, and as senior manager of chemical development for GlaxoSmithKlein plc, a pharmaceutical
and biotechnology company. Dr. Tapolczay served as Executive Vice President at Cambridge Discovery Chemistry, where he was responsible
for the rapid growth of Cambridge Discovery Chemistry and was a key figure in two successful sales of that company, the first to Oxford
Molecular and the second to Millennium Pharmaceuticals. After this last acquisition, Dr. Tapolczay was Senior Vice President of Pharmaceutical
Sciences at Millennium Pharmaceuticals, with responsibility for over 230 scientists. On leaving Millennium, Dr. Tapolczay was a founder
and Chairman of Pharmorphix Ltd., which was acquired by Sigma Aldrich Fine Chemicals in August